GlassScriptPhysician profile
Matthew J Oman
NPI 1548461155
$10,624.88
in general payments reported to CMS, 2019-2025
34 companies · $3,153 in 2025
The $3,153 reported for 2025 was more than what 87% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $375 · 2020: $584 · 2021: $816 · 2022: $1,472 · 2023: $1,686 · 2024: $2,538 · 2025: $3,153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,377.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,749.13 | 2019-2025 | |
| Janssen Biotech, INC. | $1,169.72 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $1,007.06 | 2019-2025 | Entyvio, Eohilia |
| Aimmune Therapeutics, INC. | $729.70 | 2024-2025 | Zenpep, Vowst |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $674.95 | 2020-2025 | Xifaxan, Trulance |
| Genzyme Corporation | $607.32 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $384.25 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $239.20 | 2024-2025 | Rezdiffra, Resmetirom |
| Nestle Healthcare Nutrition INC. | $236.46 | 2022-2023 | |
| Qol Medical, LLC | $167.92 | 2023-2025 | Sucraid, Sucraid |
| Lilly USA, LLC | $150.87 | 2024-2025 | Omvoh |
| Lucid Diagnostics INC. | $144.42 | 2023 | |
| Medtronic USA, INC. | $138.90 | 2020 | |
| Pfizer INC. | $125.95 | 2019-2024 | |
| Celltrion USA INC. | $117.26 | 2025 | Vegzelma |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $106.98 | 2024-2025 | Voquezna |
| Covidien LP | $100.43 | 2019 | |
| Gilead Sciences, INC. | $89.19 | 2019-2022 | |
| Fresenius Kabi USA, LLC | $85.33 | 2023-2025 | Idacio |
| Ferring Pharmaceuticals INC. | $83.66 | 2022-2024 | Rebyota |
| Daiichi Sankyo INC. | $74.23 | 2020-2022 | |
| Welch Allyn | $64.43 | 2020 | |
| Braintree Laboratories, INC. | $61.77 | 2019-2024 | Sutab, Suflave |
| Intercept Pharmaceuticals, INC. | $57.17 | 2020-2025 | |
| Redhill Biopharma INC. | $46.85 | 2020-2023 | Aemcolo, Talicia, Movantik |
| Medtronic, INC. | $39.12 | 2021-2024 | Pillcam |
| Celgene Corporation | $33.77 | 2024 | Zeposia |
| Olympus America INC. | $33.61 | 2019-2020 | |
| Boston Scientific Corporation | $24.19 | 2020 | |
| Alfasigma USA, INC. | $23.13 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $21.28 | 2024 | Andexxa |
| Ironwood Pharmaceuticals, INC | $16.22 | 2022 | |
| Shionogi INC | $14.86 | 2019 | |
| Organon LLC | $5.55 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Oman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.